EA202192527A1 - COMPOUNDS AND METHODS FOR REDUCING KCNT1 EXPRESSION - Google Patents
COMPOUNDS AND METHODS FOR REDUCING KCNT1 EXPRESSIONInfo
- Publication number
- EA202192527A1 EA202192527A1 EA202192527A EA202192527A EA202192527A1 EA 202192527 A1 EA202192527 A1 EA 202192527A1 EA 202192527 A EA202192527 A EA 202192527A EA 202192527 A EA202192527 A EA 202192527A EA 202192527 A1 EA202192527 A1 EA 202192527A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- compounds
- methods
- kcnt1
- reducing
- pharmaceutical compositions
- Prior art date
Links
Abstract
Предложены соединения, способы и фармацевтические композиции для снижения количества или активности РНК KCNT1 в клетке или у субъекта и в некоторых случаях для снижения количества белка KCNT1 в клетке или у субъекта. Такие соединения, методы и фармацевтические композиции полезны для облегчения по меньшей мере одного симптома или признака неврологического заболевания. Такие симптомы и отличительные признаки включают судороги, энцефалопатию и поведенческие аномалии. Неограничивающими примерами неврологических заболеваний, при которых полезны эти соединения, способы и фармацевтические композиции, являются эпилепсия младенчества с мигрирующими фокальными припадками (EIMFS), аутосомно-доминантная ночная лобная эпилепсия (ADNFLE), синдром Веста и синдром Охтахара.Compounds, methods, and pharmaceutical compositions are provided for reducing the amount or activity of KCNT1 RNA in a cell or subject and, in some cases, for reducing the amount of KCNT1 protein in a cell or subject. Such compounds, methods, and pharmaceutical compositions are useful in alleviating at least one symptom or sign of a neurological disease. Such symptoms and hallmarks include seizures, encephalopathy, and behavioral abnormalities. Non-limiting examples of neurological diseases for which these compounds, methods, and pharmaceutical compositions are useful are epilepsy of infancy with migrating focal seizures (EIMFS), autosomal dominant nocturnal frontal epilepsy (ADNFLE), West's syndrome, and Ochtahar's syndrome.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962884501P | 2019-08-08 | 2019-08-08 | |
PCT/US2020/022680 WO2020190740A1 (en) | 2019-03-15 | 2020-03-13 | Compounds and methods for reducing kcnt1 expression |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202192527A1 true EA202192527A1 (en) | 2021-12-13 |
Family
ID=80631201
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202192527A EA202192527A1 (en) | 2019-08-08 | 2020-03-13 | COMPOUNDS AND METHODS FOR REDUCING KCNT1 EXPRESSION |
Country Status (1)
Country | Link |
---|---|
EA (1) | EA202192527A1 (en) |
-
2020
- 2020-03-13 EA EA202192527A patent/EA202192527A1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA202190140A1 (en) | CONNECTIONS AND METHODS FOR LRRK2 EXPRESSION REDUCTION | |
Matilla-Dueñas et al. | Consensus paper: pathological mechanisms underlying neurodegeneration in spinocerebellar ataxias | |
BR0314760A (en) | Organic compounds | |
BR112014004741A2 (en) | at least one chemical entity; pharmaceutical composition; use of a therapeutically effective amount of at least one chemical entity; packaged pharmaceutical composition | |
EA202092500A1 (en) | CONNECTIONS AND METHODS FOR REDUCING EXPRESSION ATXN3 | |
EA201190043A1 (en) | IMIDAZOPIRASINE INHIBITORS SYK | |
BR112019007383A2 (en) | compounds and methods for reducing atxn3 expression | |
BR112012018500A2 (en) | some quinurenine-3-monooxygenase inhibitors, pharmaceutical compositions and methods of use thereof | |
Prachayasittikul et al. | P-glycoprotein transporter in drug development | |
EP2331095A4 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
Nashine | Potential therapeutic candidates for age-related macular degeneration (AMD) | |
MX2011006091A (en) | Imidazopyrazine syk inhibitors. | |
BR112014027571A2 (en) | Methods for the treatment of diabetic retinopathy and other eye diseases | |
EA201070035A1 (en) | MODULATING SIRTUIN CONNECTIONS | |
EA201070579A1 (en) | СОЛЮБИЛИЗИРОВАННЫЕ ТИАЗОЛОПИРИДИНЫ | |
JOP20210254A1 (en) | Compounds and methods for reducing kcnt1 expression | |
Cuadrado-Tejedor et al. | Epigenetic drugs in Alzheimer’s disease | |
RU2018115781A (en) | CONDITIONALLY ACTIVE POLYPEPTIDES | |
Esteves et al. | Discovery of therapeutic approaches for polyglutamine diseases: a summary of recent efforts | |
Busquets et al. | Role of c-Jun N-Terminal Kinases (JNKs) in epilepsy and metabolic cognitive impairment | |
EA202192527A1 (en) | COMPOUNDS AND METHODS FOR REDUCING KCNT1 EXPRESSION | |
BR112023001624A2 (en) | COMPOUNDS AND METHODS TO REDUCE APP EXPRESSION | |
EA200900923A1 (en) | APPLICATION OF NEUROPROTECTIVE CONNECTIONS IN THE OBTAINING OF MEDICINES FOR THE TREATMENT OF NEURODEGENERATIVE Diseases | |
WO2021263082A3 (en) | Compounds and methods for reducing kcnt1 expression | |
Dorn | Reversing Dysdynamism to Interrupt Mitochondrial Degeneration in Amyotrophic Lateral Sclerosis |